{"id":7326,"date":"2025-02-24T19:37:03","date_gmt":"2025-02-24T19:37:03","guid":{"rendered":"https:\/\/cardiologylibrary.com\/?product=cleveland-clinic-cardiovascular-update-2025"},"modified":"2026-01-18T23:57:02","modified_gmt":"2026-01-18T23:57:02","slug":"cleveland-clinic-cardiovascular-update-2025","status":"publish","type":"product","link":"https:\/\/cardiologylibrary.com\/?product=cleveland-clinic-cardiovascular-update-2025","title":{"rendered":"Cleveland Clinic Cardiovascular Update 2025"},"content":{"rendered":"<table cellspacing=\"0\" cellpadding=\"0\">\n<colgroup>\n<col width=\"787\" \/>\n<col width=\"641\" \/><\/colgroup>\n<tbody>\n<tr>\n<td colspan=\"2\" bgcolor=\"#CCCCCC\"><strong>Session 1: Prevention and Management of Cardiovascular Risk, Part 1<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"918\">Tools in CVD Prevention and Risk Management: To Test or Not to Test? Lp(a),apoB, Non HDL-C<\/td>\n<td>Dennis Bruemmer, MD, PhD<\/td>\n<\/tr>\n<tr>\n<td>Statin Initiation for Primary Prevention Among Statin Na\u00efve Adults and Reasons for Nonadherence<\/td>\n<td>Vikas Sunder, MD<\/td>\n<\/tr>\n<tr>\n<td>When Statins Are Not Enough \u2013 Non-statin Lipid Lowering Therapies to Manage Residual Risk<\/td>\n<td>Ashish Sarraju, MD<\/td>\n<\/tr>\n<tr>\n<td>Managing Anti-Hyperglycemic and CV Risk Reduction Agents in Patients With Diabetes: SGLT2i or GLP1RA or Both?<\/td>\n<td>Dennis Bruemmer, MD, PhD<\/td>\n<\/tr>\n<tr>\n<td>Weight Loss Pharmacotherapy: Utilizing Current Therapies and Exploring the Next Generation of Weight Loss Medications<\/td>\n<td>Steve Nissen, MD<\/td>\n<\/tr>\n<tr>\n<td>Keto, Low Carb, Plant Based, IF: Controversies in the Evidence for the \u201cBest \u201cDiet: What is the Evidence and How to Apply in Clinical Practice<\/td>\n<td>Julia Zumpano, RD, LD<\/td>\n<\/tr>\n<tr>\n<td>Old and Evolving Strategies for Treatment-Resistant Hypertension<\/td>\n<td>Luke Laffin, MD<\/td>\n<\/tr>\n<tr>\n<td>Social Determinants of Health and Cardiovascular Disease: Current State and Future Directions<\/td>\n<td>Lee Kirksey, MD<\/td>\n<\/tr>\n<tr>\n<td>Panel Discussion\/Q&A<\/td>\n<td>Session Faculty<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" bgcolor=\"#CCCCCC\"><strong>Session 2: Prevention and Management of Cardiovascular Risk, Part 2<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Hormone Therapy and Heart Health: Debunking Myths, Embracing Evidence<\/td>\n<td width=\"246\">Luke Laffin, MD<\/td>\n<\/tr>\n<tr>\n<td>The Intersection of Cardiovascular Disease and Chronic Kidney Disease: Strategies for Reducing Cardiovascular Risk<\/td>\n<td>Crystal Gadegbeku, MD<\/td>\n<\/tr>\n<tr>\n<td>Who Should Get a CAC? How Often? How to Use the Results to Assess Risk?<\/td>\n<td>Milind Desai, MD<\/td>\n<\/tr>\n<tr>\n<td>Management of CV Issues in the Elderly: Geriatric Cardiology<\/td>\n<td>Ardeshir Hashmi, MD<\/td>\n<\/tr>\n<tr>\n<td>Population Health Management: Interventions to Control Cardiovascular Disease Risk Factors: Current Status<\/td>\n<td>LeRoi Hicks, MD<\/td>\n<\/tr>\n<tr>\n<td>Panel Discussion\/Q&A<\/td>\n<td>Session Faculty<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" bgcolor=\"#CCCCCC\"><strong>Session 3: Special Populations<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Cardiac Disease Remains the Leading Cause of Mortality in Women: What are we Doing to Address This?<\/td>\n<td>Vikas Sunder, MD<\/td>\n<\/tr>\n<tr>\n<td>Cardiovascular Disease and Pregnancy: Optimizing Maternal and Fetal Health<\/td>\n<td>Deirdre Mattina, MD<\/td>\n<\/tr>\n<tr>\n<td>Competitive Sports Participation in Athletes with Heart Disease: Evaluation and Management<\/td>\n<td>Tamanna Singh, MD<\/td>\n<\/tr>\n<tr>\n<td>Cardio-oncology: Optimizing the Balance Between Cancer Outcomes and Cardiac Success<\/td>\n<td>Patrick Collier, MD, PhD<\/td>\n<\/tr>\n<tr>\n<td>Panel Discussion\/Q&A<\/td>\n<td>Session Faculty<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" bgcolor=\"#CCCCCC\"><strong>Session 4: Essentials of Cardiovascular Disease<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Role of Advanced Imaging for Ischemic Heart Disease: CT, CMR, Nuclear and Advanced Echocardiography<\/td>\n<td>Saberio Lo Presti Vega, MD<\/td>\n<\/tr>\n<tr>\n<td>Creating a Pathway for the Management of Stable Angina in Your Clinic: Structured Risk Assessment and Clinical Decision Making<\/td>\n<td>Ben Alencherry, MD<\/td>\n<\/tr>\n<tr>\n<td>ANOCA, INOCA, MINOCA: What Does It All Mean? Diagnostic Testing and Therapeutic Management<\/td>\n<td>Khalid Ziada, MD<\/td>\n<\/tr>\n<tr>\n<td>How Do I Manage my Post MI Patient (Including DAPT Guidelines\/Duration\/CardiacRehab)<\/td>\n<td>Venu Menon, MD<\/td>\n<\/tr>\n<tr>\n<td>Cardiac Rehab: Why it is Critical and How Can We Improve Access and Compliance?<\/td>\n<td>Erik Van Iterson, PhD, MS<\/td>\n<\/tr>\n<tr>\n<td>Peripheral Artery Disease: Assessment and Clinical Decision Making<\/td>\n<td>Lee Kirksey, MD<\/td>\n<\/tr>\n<tr>\n<td>Panel Discussion\/Q&A<\/td>\n<td>Session Faculty<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" bgcolor=\"#CCCCCC\"><strong>Session 5: Structural Heart Disease<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Aortic Stenosis: Diagnosis and Management in the Modern Era<\/td>\n<td>Samir Kapadia, MD<\/td>\n<\/tr>\n<tr>\n<td>MR: How to Diagnose and Manage Mitral Valve Disease: When to Refer? What are the Options<\/td>\n<td width=\"246\">L. Leonardo Rodriguez, MD<\/td>\n<\/tr>\n<tr>\n<td>What to Know About the Natural History of Tricuspid Regurgitation: Current and Future Management Strategies<\/td>\n<td>Amar Krishnaswamy, MD<\/td>\n<\/tr>\n<tr>\n<td>Bicuspid and Aneurysm-Associated Aortic Valve Disease: Timing of Intervention and the Role of Family Screening<\/td>\n<td>Milind Desai, MD<\/td>\n<\/tr>\n<tr>\n<td>Guidelines for Anticoagulation Following Structural Heart Therapies<\/td>\n<td>Grant Reed, MD, MSc<\/td>\n<\/tr>\n<tr>\n<td>Hypertrophic Cardiomyopathy: Co-management in the Era of Emerging Precision Therapies<\/td>\n<td>Milind Desai, MD<\/td>\n<\/tr>\n<tr>\n<td>Panel Discussion\/Q&A<\/td>\n<td>Session Faculty<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" bgcolor=\"#CCCCCC\"><strong>Session 6: Heart Failure<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Heart Failure Stages, Phenotypes and Diagnosis and How to Screen for HF in the Primary Care Setting<\/td>\n<td>Randall Starling, MD<\/td>\n<\/tr>\n<tr>\n<td>HFrEF: Essentials of Guideline Directed Medical Therapy Initiation and Titration<\/td>\n<td>Amanda Vest, MBBS<\/td>\n<\/tr>\n<tr>\n<td>Managing Comorbidities in HF: Frailty, Anemia, Sleep Apnea, AF, Obesity<\/td>\n<td>Karlee Hoffman, DO<\/td>\n<\/tr>\n<tr>\n<td>Essentials of Diagnosis and Management for HFpEF<\/td>\n<td>Sanjeeb Bhattacharya, MD<\/td>\n<\/tr>\n<tr>\n<td>Diagnosis and Management of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)<\/td>\n<td>Mazen Hanna, MD<\/td>\n<\/tr>\n<tr>\n<td>Strategies to Enhance GDMT Implementation and Adherence<\/td>\n<td>M. Trejeeve Martyn, MD<\/td>\n<\/tr>\n<tr>\n<td>Managing Long Term LVADs and Transplant Recipients in the Community Setting<\/td>\n<td>Ike Okwuosa, MD<\/td>\n<\/tr>\n<tr>\n<td>The Importance of Collaboration Between EP and HF: CRT and Novel Pacing<\/td>\n<td>Niraj Varma, MD, PhD<\/td>\n<\/tr>\n<tr>\n<td>Panel Discussion\/Q&A<\/td>\n<td>Session Faculty<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" bgcolor=\"#CCCCCC\"><strong>Session 7: Heart Rhythm<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Diagnosis and Management of New-Onset Atrial Fibrillation<\/td>\n<td>Mohamed Kanj, MD<\/td>\n<\/tr>\n<tr>\n<td>AF and Left Atrial Appendage Closure: Current and Future Directions<\/td>\n<td>Mohamed Kanj, MD<\/td>\n<\/tr>\n<tr>\n<td>What I Need to Know to Evaluate and Manage the Patient With PVCs and SVT<\/td>\n<td>Pasquale Santangeli, MD, PhD<\/td>\n<\/tr>\n<tr>\n<td>Evaluation and Management of Syncope in the Young Adult<\/td>\n<td>Kenneth Mayuga, MD<\/td>\n<\/tr>\n<tr>\n<td>Follow-Up of Pacemakers and ICDs For the Non-Electrophysiologist<\/td>\n<td>Kevin F. Kwaku, MD, PhD<\/td>\n<\/tr>\n<tr>\n<td>Wearables for Arrhythmia Care: Current Challenges and Future Prospects<\/td>\n<td>Niraj Varma, MD, PhD<\/td>\n<\/tr>\n<tr>\n<td>Panel Discussion\/Q&A<\/td>\n<td>Session Faculty<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Session 1: Prevention and Management of Cardiovascular Risk, Part 1 Tools in CVD Prevention and Risk Management: To Test or Not to Test? Lp(a),apoB, Non HDL-C Dennis Bruemmer, MD, PhD Statin Initiation for Primary Prevention Among Statin Na\u00efve Adults and Reasons for Nonadherence Vikas Sunder, MD When Statins Are Not Enough \u2013 Non-statin Lipid Lowering [&hellip;]<\/p>\n","protected":false},"featured_media":7711,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[66],"product_tag":[],"class_list":{"0":"post-7326","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-course","8":"first","9":"instock","10":"sale","11":"downloadable","12":"virtual","13":"purchasable","14":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/cardiologylibrary.com\/index.php?rest_route=\/wp\/v2\/product\/7326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cardiologylibrary.com\/index.php?rest_route=\/wp\/v2\/product"}],"about":[{"href":"https:\/\/cardiologylibrary.com\/index.php?rest_route=\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/cardiologylibrary.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7326"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cardiologylibrary.com\/index.php?rest_route=\/wp\/v2\/media\/7711"}],"wp:attachment":[{"href":"https:\/\/cardiologylibrary.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7326"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/cardiologylibrary.com\/index.php?rest_route=%2Fwp%2Fv2%2Fproduct_brand&post=7326"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/cardiologylibrary.com\/index.php?rest_route=%2Fwp%2Fv2%2Fproduct_cat&post=7326"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/cardiologylibrary.com\/index.php?rest_route=%2Fwp%2Fv2%2Fproduct_tag&post=7326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}